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Wine Allergy in a Wine-Growing District
Tolerance Induction in a Patient With Allergy to Grape
Lipid-Transfer Protein
Susanne G. Scha¨d, MD, Jiri Trcka, MD, Iris Lauer, PhD, Stephan Scheurer, PhD, and
Axel Trautmann, MD
Background: An IgE-mediated allergy against a lipid-transfer pro-
tein of grapes was the cause of repeated severe anaphylaxis in a
patient after consumption of grapes, wine, and raisins.
Objective: Although the patient was aware of her grape allergy,
avoidance proved difficult and accidental anaphylaxis occurred.
Furthermore, wine allergy in a wine-growing district means a
non-negligible restriction of quality of life.
Methods: Although there is little data on specific oral tolerance
induction (SOTI) in lipid-transfer protein (LTP) allergy, SOTI with
increasing doses starting from approximately 20 mg of grapes was
done. For follow-up, skin tests, grape-specific IgE and IgG4, baso-
phil activation tests, and immunoblotting were performed.
Results: Within 3 days the patient reached tolerance to the daily
maintenance dose of 20 g of grapes (about 3 grape pieces) without
anaphylaxis symptoms. Two months later, a controlled challenge
with a total of 66.5 mL of white wine was tolerated. Grape-specific
IgE stayed stable at 2.37 kU/L (class 2) and grape-specific IgG4 was
first detectable 21 months after SOTI. Prick-to-prick skin tests
continued to be positive to grapes, to raisins, and to white and red
wine. The basophil activation test still showed strong IgE-mediated
activation of basophils after stimulation with grape extract. Immu-
noblotting still detected IgE binding to a 8-kDa protein.
Conclusions: We performed SOTI in a patient with severe IgE-
mediated allergy against the LTP Vit v 1 of grapes and reduced the
risk of anaphylaxis because of accidental intake of any kind of
grapes. However, underlying mechanisms of SOTI and maintenance
of the established tolerance are still not known.
Key Words: specific oral tolerance induction, grape allergy, wine
allergy, food allergy, anaphylaxis, lipid-transfer protein
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INTRODUCTION
Allergy to grapes has been rarely reported despite grapesbeing widely consumed as fresh fruit, juice, and wine.1–3
The major allergens of grape and wine have been identified as
endochitinase 4A, a lipid-transfer protein (LTP), and a thauma-
tin-like protein.4 Although the majority of infants and young
children outgrow their allergy to, for example, cow’s milk and
hen’s egg, food allergy in adults to, for example, fruits such as
grapes typically persists for a lifetime.5 In routine clinical set-
tings treatment for IgE-mediated grape allergy is avoidance of
grapes with adequate pharmacotherapy in the event of accidental
ingestion.6 Strict avoidance of any kind of grapes is rather
difficult and may lead to severe anaphylaxis in the case of
dietary failure. Interestingly, many of the patients who experi-
ence life-threatening food-induced anaphylaxis are aware of
their food allergies. In a study conducted in the United States,
allergy to the triggering food was known in 41% of emergency
room visits for allergic reactions to foods.7 This highlights the
search for additional therapeutic strategies beneath the impor-
tance of allergen avoidance.
Subcutaneous injection immunotherapy is not recom-
mended for food allergy because of the high incidence of
systemic adverse reactions.8–10 Achieving tolerance by spe-
cific oral tolerance induction (SOTI) is a promising treatment
option in patients with food allergy, but is still controversial
and no standardized protocols are yet available. During SOTI,
the offending food is administered orally, starting with very
low doses, followed by a steady increase up to an amount
equivalent to a usual daily oral intake. Successful SOTI was
repeatedly reported with cow’s milk and hen’s egg, which are
not LTP allergens. Thus far, Enrique et al11 published a
randomized, double-blind, placebo-controlled study of pa-
tients allergic to Spanish hazelnut who were treated success-
fully by an oral/sublingual immunotherapy with standardized
hazelnut extract. Major allergens in these patients were iden-
tified as Cor a 1, a protein homologous to the Bet v 1 allergen,
and Cor a 8, a hazelnut lipid-transfer protein, not associated
with birch pollen allergy.12
Here, we report successful SOTI in a patient with
IgE-mediated allergy against a LTP of grapes, identified as
Vit v 1 (Vitis vinifera  grape wine, botanical family Vita-
ceae).13 The results of in vivo and in vitro diagnostic proce-
dures before and after SOTI demonstrated, on the one hand,
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unchanged IgE-mediated sensitization, and on the other hand,
SOTI-induced grape-specific IgG4 antibodies.
METHODS
Patient
We recently reported on a now 34-year-old German
woman who had severe anaphylactic reactions after con-
sumption of about 100 mL of wine, 5 pieces of fresh white or
blue grapes, and 3 pieces of raisins. Her last episode with
palmoplantar pruritus, angioedema of the lips and tongue,
dyspnea, dysphagia, and tachycardia was 7 years ago, 60
minutes after eating about 3 pieces of raisins. Shortly after
this last episode, our study could demonstrate that her ana-
phylactic symptoms were due to an IgE-mediated allergy
against the LTP Vit v 1 of grapes without associated polli-
nosis.13 She had to avoid all kinds of grapes, raisins, grape
juice, wine, and champagne for 3 years before specific oral
tolerance induction was performed.
SOTI
General principles of our SOTI protocol are as follows:
(a) the time interval between SOTI and anaphylaxis symp-
toms has to be at least 4 weeks; (b) during the entire SOTI the
patient is monitored and equipment for emergency treatment
is available; (c) the dose increases stepwise in 3 consecutive
days to the maintenance dose; (d) absolute and relative
contraindications for SOTI are strictly adhered to; (e) before
SOTI written informed consent is obtained. The schedule
consisted of administering increasing amounts of white
grapes starting from 19.5 mg of grapes ground in a mortar
and diluted with 10 mL of 0.9% sodium chloride (Table 1).
The grape amount was doubled every 30 minutes to 625 mg
of grapes on the first day. On the second day, the dose was
continuously doubled every 30 minutes starting from the last
dilution on the day before up to 20 g of grapes diluted with
10 mL of 0.9% sodium chloride. On day 3 the maximum dose
of 3 pieces of white grapes (20 g) was given.
Challenge Test
Two months later, a blinded, not placebo-controlled
oral challenge test was performed starting from 0.5 mL of
undiluted white wine. The dose was then increased every 30
minutes to 1.0, 5.0, 10, and 50 mL.
Skin Tests
Prick-to-prick tests with white and blue grapes, raisins,
and white and red wine were performed before and 3 months
after successful SOTI. The prick-to-prick tests were done as
previously described.13 The test was defined as “1” positive
reaction with a wheal diameter of 2–4 mm, “2” positive
reaction with a wheal diameter of 4–6 mm, and “3” positive
reaction with a wheal diameter more than 6 mm. All tests were
performed according to the EAACI recommendations.14
Grape-Specific IgE/IgG4
Serum was analyzed for grape-specific IgE and specific
IgG4 antibodies (f259) by the Phadia CAP System (Phadia
AB, Uppsala, Sweden) according to the manufacturer’s
instructions.
Grape Extract
Protein extract was prepared from fresh white grapes by
a low-temperature acetone powder method as previously
described.13
Basophil Activation Test
The basophil activation test (BAT) was performed as
previously described.13 Blood (5 mL) from the patient and a
control (nonallergic) person was used within 6 hours of blood
sampling for the BAT, which is based on the in vitro allergen-
induced activation of basophils. The assay was performed
using a kit according to the manufacturer’s instructions (Bu¨-
hlmann Laboratories, Basel, Switzerland). Briefly, leukocytes
were stimulated in vitro with grape extract and commercial
grape antigen (555; Allergopharma, Freiburg, Germany) at
concentrations ranging from 108 to 1 g/mL and from
0.5  109 to 0.5 g/ml, respectively, control antigen
(yellow jacket), and positive control (activating anti-FcRI
antibody). The cells were double-stained with anti-CD63-
Phycoerythrin and anti-IgE-fluorescein isothiocyanate-labeled
antibodies. Activated basophils (CD63 and IgE double-pos-
itive cells) were counted by flow cytometry at 488 nm on a
FACSCalibur (Becton Dickinson Immunocytometry Systems,
Mansfield, Mass., USA) using Cell Quest Software.
Immunoblotting
Briefly, grape extract (70 g of protein per cm) was
separated by SDS-PAGE (17.5%) according to La¨mmli under
nonreducing conditions and electroblotted onto nitrocellulose
membranes (0.2 mm; Schleicher und Schu¨ll, Dassel, Ger-
many) (400 mA, 50 minutes) blocked in Tris-buffered saline/
0.3% Tween 20 (Sigma-Aldrich, Steinheim, Germany).
Transfer was controlled by reversible staining of membranes
with Ponceau S (Sigma Diagnostics, St. Louis, USA). Mem-
branes were incubated with the patient’s 1:7 diluted sera and
bound IgE antibodies were detected with mouse-antihuman
IgE-biotin (1:1.500; KPL, Gaithersburg, Md, USA) followed
by streptavidin-AP (1:3.000; Caltag, Burlingame, Calif.,
USA). Bound antibodies were visualized with nitroblue tet-
razolium/5-bromo-4-chloro-3-indolyl phosphate as substrate
in 0.1 M Tris-buffered saline, pH 9.5, according to the
manufacturer’s instructions (Biorad, Munich, Germany).
TABLE 1. SOTI Protocol for Grape Allergy
Parameter SOTI procedure
Starting dose of grape 10 mL of 20 g of grapes diluted 1:1024
with 0.9% sodium chloride, corresponding
to 19.5 mg of grapes
Time between steps 30 minutes
Increment of steps Doubling doses
Number of steps 14
Time for whole procedure 3 days
Maximal dose 20 g of grapes
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RESULTS
SOTI and Challenge Test
After successful completion of SOTI without any
symptoms, the patient maintained the achieved tolerance by a
daily maintenance dose of 20 g of white or blue grapes (about
3 pieces of grape). Two months after SOTI, she tolerated a
challenge test with a total dose of 66.5 mL of white wine. So
far, 4 years after SOTI, no anaphylaxis symptoms occurred
through accidental intake of any kind of grapes. A double-
blind, placebo-controlled oral grape challenge further testing
tolerance was refused by the patient because of considerable
fear of anaphylaxis symptoms.
Skin Test and Grape-Specific IgE/IgG4
Prick-to-prick tests revealed positive reactions to fresh
white (1) before SOTI 2 and blue grapes (1) 2, to
raisins (2) 3, and to white (1) 1 and red wine (1)
2. Specific IgE to grape was 2.37 kU/L (class 2) 2.43
kU/L, class 2 and specific IgG4 to grape was 160 gA
(assay-specific)/L 21 months after SOTI not detectable be-
fore SOTI.
BAT
Activation of the patient’s basophils after stimulation
with self-prepared grape extract at different concentrations
yielded 93.0% and 89.7% activated basophils at 0.1 g/mL
and 105 g/ml, respectively, and with commercial grape
antigen 89.1% and 17.4% activated basophils at 0.5  101
and 0.5  102 g/mL, respectively. Background of the
negative control was measured as 9.6%. In grape extract- and
commercial grape antigen-stimulated samples of the control
person, no basophil activation was observed, that is, 5.7%
activated basophils at 0.1 g/mL of grape extract and 5.1%
activated basophils at 0.5  101 g/mL of commercial
grape antigen. In both the patient and control person, stimu-
lation with control antigen (yellow jacket) was negative
(2.9% and 8.0%), whereas positive controls using activating
anti-FcRI antibody confirmed basophil activation (93.0%
and 92.1%).
Immunoblotting
Before and after SOTI grape-specific IgE was further
analyzed by immunoblotting using the self-prepared grape
extract. Figure 1 showed only one single IgE-reactive band
with an apparent molecular weight of 8 kDa (lanes 1 and 2),
whereas for the nonallergic control no IgE antibody reactivity
was detectable (lane NC). The IgE reactive band was com-
pletely inhibited by preincubation with 15 g of cherry LTP
(lane 3)—no inhibition with bovine serum albumin as control
(lane 2)—suggesting that this band represents the LTP Vit v 1.
FIGURE 1. Immunoblotting. Lane M, molecular-weight marker proteins; lane BC, buffer control; lane NC, nonallergic con-
trol; lane 1, IgE binding of patient allergic to wine; lane 2, preincubation of patient’s serum with 15 g of BSA; lane 3, prein-
cubation of patient’s serum with 15 g of purified recombinant cherry LTP Pru av 3; lanes 4–6, positive control serum (pa-
tient from Spain with known IgE antibody reactivity to different LTPs: lane 4, without inhibitor; lane 5, preincubation with 15
g of BSA; lane 6, preincubation with 15 g of rPru av 3).
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In a comparison of immunoblotting experiments before and after
SOTI, no significant reduction of IgE-antibody reactivity to the
grape LTP could be observed.13
DISCUSSION
The mainstay in the management of IgE-mediated food
allergy is strict avoidance of exposure to the offending
allergen.15 However, this approach can be difficult in the case
of common food or when the allergen is hidden and not
necessarily labeled in commercial food. It should always be
remembered that many of the most serious allergic reactions
occur in restaurants and other food-service establishments
where full-label disclosure of ingredients is typically not
practiced.10,16 Furthermore, the elimination diet may reduce
quality of life and can induce eating disorders with psycho-
logical problems.
Given the high incidence of systemic reactions using
subcutaneous immunotherapy for IgE-mediated peanut aller-
gy,17 oral immunotherapy has been investigated as an alter-
native during the past few years. Our patient suffered from
repeated IgE-mediated anaphylaxis after ingestion of very
small amounts of any kind of grapes. She lives in a wine-
growing district where numerous festivities take place in a
given year concerning the wine cultivated there. Furthermore,
she takes vacations regularly in Italy and enjoys Mediterra-
nean kitchen. Therefore, the strict avoidance of wine was in
her case accompanied by a substantial restriction of her
quality of life and we decided to perform SOTI. Little is
known about SOTI in patients with IgE-mediated LTP al-
lergy. Twenty-three patients from Spain with an IgE-medi-
ated allergy to a Bet v 1-homologous hazelnut protein or to a
hazelnut LTP were treated with oral/sublingual immunother-
apy of a standardized hazelnut extract or with a saline
solution as placebo in a randomized, double-blind, placebo-
controlled study.11 For the active specific immunotherapy
group of 12 patients, the starting dose concentration was 2 
1011 mg and the final dose was 119.51 mg of hazelnut
protein. With a rushed schedule, the build-up phase was
completed in 4 days. Thereafter, mean hazelnut quantity
provoking objective symptoms increased from 2.29 to 11.56
g in the active group versus 3.49 to 4.14 g in the placebo
group.
More experiences exist for SOTI with cow’s milk,
mostly in children.18–20 Meglio et al20 reported a completely
successful SOTI with cow’s milk in 15 of 21 children
(71.4%). Although 8 of these children showed no allergic
reactions reaching the full cow’s milk intake, 7 children
presented some, mostly temporary symptoms such as mod-
erate asthma, throat pruritus, urticaria, rhinitis, abdominal and
epigastric pain, and vomiting. In the study by Patriarca et al,18
cow’s milk SOTI was successful in 4 of 6 children. In a
preliminary report on 3 patients with allergy to cow’s milk or
hen’s egg, all 3 patients reached tolerance to the maximum
dose after 37, 41, and 52 weeks.21 Recently, a 24-month egg
SOTI for children with nonanaphylactic egg allergy resulted
in increased tolerance to egg upon placebo-controlled chal-
lenges to levels higher than those found in accidental inges-
tions.22 During SOTI few patients cannot achieve the full
maintenance dose because of anaphylaxis symptoms such as
urticaria, angioedema, abdominal pain, and hypotension.20,23
However, in the majority of cases these adverse reac-
tions can be controlled by oral antihistamines.20
So far, no standardized protocols for SOTI are avail-
able. There are different regimens for SOTI with cow’s milk
reported: An ultrarush regimen starts with a low dose fol-
lowed by several steps usually every 30 minutes with a
half-logarithmic increasing dose up to 3 to 5 g of protein,
resulting in an overall time of 4 to 5 hours.24 A conventional
SOTI procedure foresees the cow’s milk administration at
home with the exception of the first doses. It starts with a very
low dose followed by less than doubling doses every 24
hours. In 2 to 3 months the maximum dose of 3 to 5 g of
protein can be achieved.21 A rush protocol of SOTI starts with
a low dose followed by doubling doses every 2 hours. This
rush-SOTI with a maximum dose of 3 to 5 g of cow’s milk
protein takes approximately 1 week.19
Regarding total time required to reach the maintenance
dose, we used a SOTI regimen modified between ultrarush
and rush. The dose of 3 pieces of whole grapes (20 g) was
achieved within 3 days and is now continued as the daily
maintenance dose. No clinical symptoms occurred during
SOTI. After 2 months of the maintenance phase, an oral wine
challenge test was also tolerated. Until now, 4 years after
SOTI and continous daily grape intake of the maintenance
dose, the patient seems to be also protected against reactions
after accidental ingestion of any kind of grapes. Her quality
of life clearly improved as she can now drink small amounts
of wine (up to 66.5 mL) and safely eats, including processed
foods and those eaten outside the home.
SOTI may induce tolerance which persists a lifetime,
but it is not clear whether the maintenance of the established
tolerance is dependent on continuous allergen intake.20,23
Rolinck-Werninghaus et al21 reported moderate systemic al-
lergic reactions in all 3 patients after re-exposure to the
allergen when maintenance treatment was stopped. The ac-
quired tolerance during/after SOTI may reflect the natural
course of the allergic disease over time or may be due to a
specific immune modulation by the SOTI procedure. Animal
studies demonstrated that the induction of anergy or deletion
of allergen-specific T cells and the activation of regulatory T
cells may be 2 possible mechanisms for achieving oral
tolerance.25 Therefore, Niggemann et al26 proposed the term
“specific oral tolerance induction” for this treatment instead
of oral immunotherapy, oral desensitization, or oral hyposen-
sitization. Few studies in humans showed significant decrease
of allergen-specific IgE after 6 months and significant in-
crease of allergen-specific IgG4 18 months later.23 In the
placebo-controlled study of Enrique et al11 laboratory data
demonstrated an increase in IgG4 and IL-10 levels after
immunotherapy in the actively treated group. Our patient
demonstrated grape-specific IgG4 for the first time 21 months
after SOTI while her specific IgE remained stable. However,
the precise mechanisms for oral tolerance induction in hu-
mans still have to be clarified.27 In our investigation, prick-
to-prick skin tests, the in vitro BAT, and the immunoblotting
confirmed despite clinical tolerance the presence of IgE
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against the LTP Vit v 1 of grapes, reflecting at least persisting
sensitization.
In conclusion, our study demonstrates that SOTI can be
a successful treatment option in patients with IgE-mediated
LTP allergy by reducing the risk of anaphylaxis and by
increasing the patient’s quality of life. Further studies are
necessary to determine the indications, protocol regimen,
time frames, immunologic changes, and the transiency of the
effect of SOTI in LTP allergy.
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